# ClinicalTrials.gov record NCT04225221

> PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct04225221-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-07-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04225221-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04225221-leuprolide-v1.json
- Content SHA-256: `4b3026ac6c18cb40ccf8216c62614283c0385534c4b6b4e3c4208d3d93abc929`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04225221 ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04225221 at 2026-07-30T19:37:37.629Z. Its registry update date was 2022-07-26, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04225221-2022-07-26-04bf757033e0`](#source-ctg-observation-nct04225221-2022-07-26-04bf757033e0))

## Sources

<a id="source-ctg-observation-nct04225221-2022-07-26-04bf757033e0"></a>
- **ClinicalTrials.gov record NCT04225221 · retained source version 2022-07-26:04bf757033e0b18a86022ef73679491c76b8759929a89f8cc3c9645d8c7d04de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04225221) (`ctg-observation-nct04225221-2022-07-26-04bf757033e0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04225221." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04225221-leuprolide-v1.json SHA-256: 4b3026ac6c18cb40ccf8216c62614283c0385534c4b6b4e3c4208d3d93abc929.